

Applicants	: KING and ZHENG	Atty. Dkt. No.	: 873-Z-US
U.S. Serial No.:	10/738,423	Art Unit	: 1633
Filed	: 12/16/2003	Date of office action	: 9/28/2007
Examiner	: Qian Janice Li	Date of response	: 10/22/2007
Page	: 3		

**Amendment(s) to the claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

1.-112. (Canceled)

113. (Amended) A method of inhibiting the growth of, or reducing the volume of a solid tumor cancer, comprising administering to a subject having a solid tumor cancer an effective amount of cytoxan or cisplatin and an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria Salmonella, wherein the Salmonella comprises an msbB<sup>-</sup> mutant.

114. (Cancelled).

115. (Previously presented) The method of claim 113 wherein, the solid tumor or cancer is either a lung cancer or colon cancer.

116. (Previously presented) The method of claim 113 wherein the subject is a mammal.

117. (Previously presented) The method of claim 113 wherein the subject is a human.

118. (Withdrawn) The method of claim 113, comprising administering an effective amount of cytoxan.

119. (Previously presented) The method of claim 113, comprising administering an effective amount of cisplatin.

Applicants	: KING and ZHENG	Atty. Dkt. No.	: 873-Z-US
U.S. Serial No.:	10/738,423	Art Unit	: 1633
Filed	: 12/16/2003	Date of office action	: 9/28/2007
Examiner	: Qian Janice Li	Date of response	: 10/22/2007
Page	: 4		

120. (New) The method of claim 113, wherein the administering of the attenuated tumor-targeted *Salmonella* msbB<sup>-</sup> and the administering of the cytoxan or cisplatin are not performed concomitantly.
121. (New) The method of claim 115, wherein the solid tumor cancer is a lung cancer.
122. (New) The method of claim 115, wherein the solid tumor cancer is a lung cancer.
123. (New) A method of inhibiting the growth of, or reducing the volume of a solid tumor cancer, comprising administering to a subject having a solid tumor cancer an effective amount of,
- (a) a pharmaceutical composition consisting essentially of an anti-cancer compound and one or more pharmaceutically acceptable carriers, and
  - (b) an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted *Salmonella*, wherein the *Salmonella* comprises an msbB<sup>-</sup> mutant.
124. (New) The method of claim 123 wherein the anti-cancer compound is cisplatin.
125. (New) The method of claim 123 wherein the anti-cancer compound is cytoxan.